-- Scott Roberts
FRIDAY, July 1 (HealthDay News) -- Lazanda (fentanyl) nasal
spray has been approved by the U.S. Food and Drug Administration to
treat breakthrough pain in adults with cancer who are already
receiving opioid therapy, drug maker Archimedes Pharma said.
Breakthrough pain occurs as an intense, unpredictable burst
among people who are already receiving therapy for chronic pain.
Lazanda is the first nasal spray containing the commonly prescribed
opioid painkiller fentanyl, the company said in a news release.
Lazanda is available in five European countries under the brand
Lazanda will be prescribed under a Risk Evaluation and
Mitigation Strategy (REMS) program to minimize instances of abuse
and addiction, the drug maker said. The program requires
pharmacies, distributors and doctors who prescribe the medication
The drug's safety and effectiveness were established in clinical
studies involving more than 500 people, Archimedes said. The most
common adverse reactions were vomiting, nausea, fever and
Archimedes, headquartered in England, has a U.S. subsidiary
based in Bedminister, N.J.
National Institute on Drug Abuse has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.